Chris Howerton
Stock Analyst at Jefferies
(1.40)
# 2,092
Out of 4,829 analysts
74
Total ratings
34.21%
Success rate
-2.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $3.53 | +126.63% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $24.62 | +220.88% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.20 | +233.33% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $1 | $0.52 | +91.94% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.48 | +23,683.78% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $4.00 | +17,900.00% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.32 | -62.12% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $11.14 | -10.23% | 1 | Feb 8, 2023 | |
| MEIP MEI Pharma | Downgrades: Underperform | $8 → $2 | $2.09 | -4.31% | 3 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $9.59 | +14.70% | 3 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $70 → $40 | $17.52 | +128.31% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $35.65 | +71.11% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $110.16 | -18.30% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.03 | +197.77% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $126 | $1.19 | +10,488.24% | 1 | Dec 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.03 | +1,841.75% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $20.18 | +227.06% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.01 | +339.12% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.37 | +1,432.85% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.00 | +2,100.00% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.28 | +1,698.42% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $17.52 | +19.86% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $7.88 | +7,265.08% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.48 | +3,954.05% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $72.14 | -77.82% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $45.27 | -40.36% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.09 | +25,377.71% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $3.53
Upside: +126.63%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $24.62
Upside: +220.88%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.20
Upside: +233.33%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $1
Current: $0.52
Upside: +91.94%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.48
Upside: +23,683.78%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $4.00
Upside: +17,900.00%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.32
Upside: -62.12%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $11.14
Upside: -10.23%
MEI Pharma
Feb 8, 2023
Downgrades: Underperform
Price Target: $8 → $2
Current: $2.09
Upside: -4.31%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $9.59
Upside: +14.70%
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $17.52
Upside: +128.31%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $35.65
Upside: +71.11%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $110.16
Upside: -18.30%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.03
Upside: +197.77%
Dec 13, 2021
Maintains: Buy
Price Target: $101 → $126
Current: $1.19
Upside: +10,488.24%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $1.03
Upside: +1,841.75%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $20.18
Upside: +227.06%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.01
Upside: +339.12%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.37
Upside: +1,432.85%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.00
Upside: +2,100.00%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.28
Upside: +1,698.42%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $17.52
Upside: +19.86%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $7.88
Upside: +7,265.08%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.48
Upside: +3,954.05%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $72.14
Upside: -77.82%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $45.27
Upside: -40.36%
May 26, 2020
Initiates: Buy
Price Target: $24
Current: $0.09
Upside: +25,377.71%